Cure8 research brief
Patients and clinicians using vedolizumab for ulcerative colitis may expect early improvement, but a lack of remission at week 2 does not reliably predict long-term failure. Clear predictive metrics are needed before using week 2 status to change therapy.
Clinicians treating UC, patients on vedolizumab or considering vedolizumab, researchers studying biologic response timing and predictors, guideline developers.
This is a Letter to the Editor commenting on a retrospective study that evaluated whether clinical remission at week 2 after starting vedolizumab predicts long-term remission (week 54) in ulcerative colitis.
The author argues that the original study needs quantitative predictive metrics (sensitivity, specificity, PPV, NPV) to inform clinical decision-making and provides calculated values from the published figure: sensitivity 58%, specificity 60%, PPV 70%, NPV 47%.
The note highlights the main caution: many patients who are not in remission at week 2 still achieve remission by week 54, consistent with vedolizumab’s known delayed onset and prior trial/post hoc findings (including VARSITY).
The author recommends future reports include predictive metrics and decision-analytic approaches before adopting week 2 remission as a rule-in or rule-out decision point.
This piece is a commentary/letter drawing on one multicenter retrospective study and prior trials/post hoc analyses. The author calculated predictive metrics from published figures rather than patient-level data; those estimates may be approximate. Vedolizumab can have a delayed onset, and some delayed responders achieve good long-term outcomes.
The letter advocates for reporting standard predictive statistics to guide therapy decisions.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study compares many targeted IBD drugs indirectly to help clarify how subcutaneous vedolizumab stacks up against other biologics and newer oral therapies — information that could inform treatment discussions for...
Early changes in stool tests (qFIT and fecal calprotectin) might help predict which biologic‑naive ulcerative colitis patients will relapse or need escalation to biologic/JAK therapy. If validated, such markers could...
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
